NICE Gives Landmark Nod To Bayer's Vitrakvi

First Histology-Independent Therapy For Patients In England

Vitrakvi is the first in a new generation of tumor-agnostic drugs to be made available on the NHS after Bayer and NICE finally reached agreement over pricing and access while more data is collected on its clinical effectiveness.

Mobile_Laptop
Bayer gets green light from NICE for Vitrakvi • Source: Shutterstock

A milestone for the tumor-agnostic market has been reached with Bayer AG's anticancer agent Vitrakvi getting the thumbs-up from England's cost-effectiveness watchdog, three months after an initial rejection.

Vitrakvi (larotrectinib), approved in the European Union in September last year, has been recommended by the National Institute for Health...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category